Selank Amidate · Research brief

What Is Selank Same as Selank Amidate? (Naming Explained)

Real Peptides Research TeamEditorial

Updated April 10, 20268 min read

53 WORDS

Short answer

A 2019 study published by the Russian Academy of Sciences found that Selank without C-terminal amidation degrades within 15 minutes of reaching systemic circulation. Rendering it biologically inactive before it can cross the blood-brain barrier. The 'Amidate' suffix doesn't denote a different compound; it specifies the structural modification that makes Selank therapeutically viable.

Key takeaways

Selank and Selank Amidate are the same compound. 'Amidate' specifies C-terminal amidation, which is present in all functional Selank preparations.
C-terminal amidation extends the peptide's half-life from under 15 minutes to approximately 30 hours by preventing enzymatic degradation.
Without amidation, carboxypeptidase B cleaves the peptide at the C-terminal arginine, fragmenting it before it can reach the brain.
All research-grade Selank sold by reputable suppliers incorporates amidation by default. The two names reflect nomenclature inconsistency in published studies, not chemical variance.
Mass spectrometry on certificates of analysis confirms the presence of the amide modification, verifying you received the active form.
The mechanism of action. BDNF upregulation and GABAergic modulation in the hippocampus. Is identical under either name.

We've synthesised thousands of peptide batches across our product line. Naming confusion like this appears frequently when peptides transition from academic literature to commercial availability. Researchers use functional descriptors (Amidate), while suppliers use brand designations (Selank). The mechanism is identical regardless of which name appears on the label.

What is Selank and is it the same as Selank Amidate?

Selank and Selank Amidate refer to the same synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from tuftsin, modified with C-terminal amidation to prevent enzymatic degradation. The Amidate designation explicitly names this structural modification. But all commercially available Selank incorporates it by default. Without amidation, the peptide would be cleaved by carboxypeptidases within minutes, making any biological effect impossible. Both names describe the research-grade anxiolytic peptide used in neuroscience studies.

The confusion stems from inconsistent nomenclature in published research. Early Russian studies used 'Selank' as the primary identifier, while Western laboratories publishing replication studies often included 'Amidate' to clarify the exact molecular form being tested. This article covers why the amidation step is non-negotiable, what the peptide actually does at the receptor level, and how to verify you're receiving the correctly modified form when sourcing research compounds.

The Molecular Structure That Defines Both Names

Selank is a synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended by three proline residues to create the heptapeptide sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The critical modification. And the reason 'Amidate' appears in some literature. Is C-terminal amidation, where the terminal carboxyl group (-COOH) is replaced with an amide group (-CONH₂). This single structural change prevents carboxypeptidase enzymes from cleaving the peptide from the C-terminus, extending the half-life from under 15 minutes to approximately 30 hours in circulation.

Without amidation, the peptide is substrate for carboxypeptidase B, which recognises basic amino acids (arginine, lysine) at the C-terminus and cleaves them sequentially. Tuftsin itself has a half-life of 2–4 minutes in plasma for this exact reason. The three-proline extension provides some steric hindrance, but carboxypeptidase activity still degrades unamidated Selank rapidly enough to prevent therapeutic concentrations from reaching the brain. The amidation step isn't an enhancement. It's the baseline requirement for function.

Every batch synthesised at facilities like Real Peptides undergoes C-terminal amidation during solid-phase peptide synthesis (SPPS) as a standard step. The final product released for research use is always the amidated form. When you see 'Selank Amidate' on a certificate of analysis, it's specifying what should already be present. Not offering a premium variant.

Why 'Selank Same as Selank Amidate' Is the Research Standard

The phrase 'Selank same as Selank Amidate' reflects naming overlap in peptide literature, not chemical variance. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1990s, with the amidated form tested in Phase II clinical trials for generalised anxiety disorder published in 2008. Western researchers replicating those studies often labelled it 'Selank Amidate' in methods sections to clarify the exact peptide modification being used. A practice that created two names for one molecule.

The functional identity is absolute. Both names describe a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂, where -NH₂ denotes the C-terminal amide. The molecular weight is 751.887 g/mol. The mechanism of action. Modulation of brain-derived neurotrophic factor (BDNF) expression and enkephalin metabolism in the hippocampus and prefrontal cortex. Is identical under either name. If a supplier distinguishes between 'Selank' and 'Selank Amidate' as separate products, they're either mislabelling or selling an inactive precursor.

Our experience working across hundreds of peptide synthesis protocols shows this naming pattern with other amidated analogs too. Melanotan II is sometimes listed as 'MT-II Acetate Amidate', though the amidation is universal. The differentiation serves no research purpose. When evaluating peptide purity via HPLC, the retention time and mass spectrometry profile for Selank and Selank Amidate are indistinguishable because they're the same compound.

How C-Terminal Amidation Changes Selank's Pharmacokinetics

C-terminal amidation shifts Selank's half-life from minutes to hours, making repeated dosing in research models feasible. Unamidated peptides face immediate degradation by serum peptidases. Enzymes that cleave peptide bonds at terminal amino acids. Carboxypeptidase B specifically targets the C-terminal arginine in the Selank sequence, removing it and exposing the next residue for cleavage. The cascade continues until the peptide is fragmented beyond bioactivity.

Amidation blocks this cascade by replacing the terminal carboxyl group with an amide, which carboxypeptidase B cannot recognise as a substrate. The result: Selank Amidate remains intact long enough to cross the blood-brain barrier via passive diffusion and saturable transport mechanisms. Pharmacokinetic studies in rodent models show detectable plasma concentrations 24 hours post-administration when using the amidated form. A timeline that enables once-daily dosing in behavioural research protocols.

The amidation also improves receptor affinity. Selank's anxiolytic effects are mediated through modulation of GABAergic transmission and upregulation of BDNF mRNA in the hippocampus. Both pathways require sustained peptide presence to achieve measurable changes in gene expression and neurotransmitter release. A peptide degrading in 15 minutes can't maintain the receptor occupancy required to alter transcription factor activity over hours. The structural stability provided by amidation is what makes Selank neurologically active.

Research-grade peptides from suppliers like Real Peptides include certificates of analysis showing molecular mass confirmation via mass spectrometry. The presence of the amide modification shifts the mass slightly compared to the free carboxylic acid form, which HPLC-MS can detect. This verification step confirms you're receiving Selank Amidate, not an inactive precursor.

Selank Same as Selank Amidate: Full Comparison

The table below clarifies the relationship between the two names and what differentiation. If any. Exists in research contexts.

Feature	Selank	Selank Amidate	Professional Assessment
Peptide Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂	Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂	Identical heptapeptide with C-terminal amide modification
C-Terminal Modification	Amidated (-CONH₂)	Amidated (-CONH₂)	Both names denote the same structural modification
Half-Life in Plasma	~30 hours (amidated form)	~30 hours (amidated form)	Functional equivalence confirmed in pharmacokinetic studies
Mechanism of Action	BDNF upregulation, GABAergic modulation	BDNF upregulation, GABAergic modulation	No mechanistic difference. Identical receptor interactions
Commercial Availability	Standard research-grade form	Standard research-grade form	'Amidate' is a descriptor, not a separate product variant
Molecular Weight	751.887 g/mol	751.887 g/mol	Mass spectrometry confirms identical molecular structure

What If: Selank Amidate Scenarios

What If I Receive Selank Labelled Without 'Amidate' — Is It Inactive?

No. Assume it's the amidated form unless the certificate of analysis explicitly states otherwise. The 'Amidate' suffix is a clarifying descriptor used inconsistently across suppliers and literature. Check the molecular weight on the COA: Selank Amidate has a molecular mass of 751.887 g/mol due to the terminal amide group, while the free acid form (which would be inactive) has a slightly higher mass of 752.871 g/mol. HPLC-MS results showing 751.887 confirm you received the correct compound regardless of labelling.

What If a Supplier Offers Both 'Selank' and 'Selank Amidate' as Separate Products?

Request certificates of analysis for both listings and compare the molecular weights and HPLC retention times. If the values are identical, they're selling the same peptide under two names. A red flag for supplier competence. If the weights differ, one product may be an inactive precursor or improperly synthesised batch. Legitimate research suppliers don't differentiate between Selank and Selank Amidate because there's no chemical basis for the distinction.

What If Published Studies Reference 'Selank' Without Mentioning Amidation?

Assume the amidated form was used unless the methods section specifies otherwise. Russian studies from the Institute of Molecular Genetics (the peptide's origin) used 'Selank' as the primary identifier, with amidation implied as the default synthesis protocol. Western replication studies often added 'Amidate' for clarity when publishing in journals with stricter peptide nomenclature standards. Both refer to the same active compound tested in Phase II trials.

The Blunt Truth About Selank Naming Confusion

Here's the honest answer: the existence of two names for Selank creates unnecessary confusion that suppliers sometimes exploit. Selank Amidate isn't a premium variant or an enhanced formulation. It's the baseline functional peptide. Any Selank preparation sold for research use must be amidated to have biological activity. If a vendor markets 'Selank Amidate' at a higher price than 'Selank', they're either uninformed about peptide chemistry or deliberately misleading buyers.

The mechanism is unambiguous. Without C-terminal amidation, the peptide degrades in circulation faster than it can reach target receptors in the brain. The published literature. Including the original Russian clinical trials and Western replication studies. Used the amidated form exclusively. There is no functional 'unamidated Selank' in legitimate research contexts. The naming split exists because researchers use different conventions when documenting peptide modifications, not because two versions of the molecule exist.

Our team has synthesised peptides across dozens of structural classes. The Selank vs Selank Amidate distinction is a documentation artifact, not a chemical reality. Verify via COA molecular weight and move on.

The real research question isn't whether Selank is the same as Selank Amidate. It's whether your supplier understands peptide synthesis well enough to deliver the correctly modified form. If they can't explain why amidation matters or provide mass spec confirmation on the COA, source elsewhere. The peptide's efficacy in modulating BDNF and GABAergic transmission depends entirely on structural integrity. And that starts with the amide group at the C-terminus.

Research-grade peptides like those available through Real Peptides undergo rigorous synthesis protocols with verification at every stage. The final product is Selank Amidate whether the label says it or not. Because that's the only form that works.

References

Peer-reviewed sources on Selank indexed in PubMed, listed for research context. Real Peptides supplies Selank for laboratory research use only.

Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of experimental biology and medicine, 2022. PMID 36322304. doi:10.1007/s10517-022-05624-x
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Current reviews in clinical and experimental pharmacology, 2021. PMID 32621722. doi:10.2174/1574884715666200704152810
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank. Bulletin of experimental biology and medicine, 2020. PMID 32651826. doi:10.1007/s10517-020-04868-9
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bulletin of experimental biology and medicine, 2019. PMID 31625062. doi:10.1007/s10517-019-04588-9
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Bulletin of experimental biology and medicine, 2019. PMID 31243679. doi:10.1007/s10517-019-04512-1
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters, 2018. PMID 30255741. doi:10.2174/0929866525666180925144642
Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Restraint Stress. Bulletin of experimental biology and medicine, 2017. PMID 28853100. doi:10.1007/s10517-017-3817-8

Questions

Selank and Selank Amidate are the same peptide — both names refer to the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro with C-terminal amidation. The ‘Amidate’ suffix explicitly identifies the amide modification that prevents enzymatic degradation, but all functional Selank preparations incorporate this modification by default. The naming difference reflects inconsistent nomenclature in research literature, not chemical variance.

Western researchers often added ‘Amidate’ to peptide names when publishing replication studies to clarify the exact molecular form being tested, following stricter peptide nomenclature standards in international journals. Original Russian studies from the Institute of Molecular Genetics used ‘Selank’ as the primary identifier, with amidation implied as the standard synthesis protocol. Both names describe the same amidated heptapeptide used in clinical trials.

Unamidated Selank degrades within 15 minutes of reaching systemic circulation due to carboxypeptidase B cleavage at the C-terminal arginine, rendering it biologically inactive before it can cross the blood-brain barrier. The peptide fragments sequentially from the C-terminus until no functional structure remains. C-terminal amidation is not optional — it’s the modification that makes Selank pharmacologically viable.

Check the certificate of analysis for molecular weight confirmation via mass spectrometry — Selank Amidate has a molecular mass of 751.887 g/mol due to the terminal amide group, while the free acid form shows 752.871 g/mol. HPLC-MS results displaying 751.887 confirm the presence of C-terminal amidation regardless of product labelling. Reputable suppliers include this verification on every COA.

Amidation doesn’t change the mechanism of action — it enables it. Selank modulates BDNF expression and GABAergic transmission in the hippocampus and prefrontal cortex, but these effects require sustained peptide presence over hours to alter gene transcription and neurotransmitter release. Without amidation extending the half-life from minutes to ~30 hours, the peptide degrades before achieving receptor occupancy long enough to produce measurable neurological effects.

No established research protocol uses unamidated Selank because it lacks biological activity in vivo. The original clinical trials and all subsequent pharmacological studies used the amidated form exclusively. Unamidated Selank might appear in peptide synthesis intermediate stages during SPPS, but it’s never the final research-grade product released for testing.

There is no difference — both names refer to the amidated peptide with a plasma half-life of approximately 30 hours in rodent models. The question itself reflects the naming confusion: ‘Selank’ and ‘Selank Amidate’ describe the same compound. An unamidated version (which wouldn’t be called either name commercially) would have a half-life under 15 minutes due to rapid enzymatic cleavage.

Yes, because they’re identical. Any published protocol using ‘Selank’ employed the amidated form — the naming variance is documentation inconsistency, not a methodological distinction. Dosing schedules, administration routes, and outcome measures apply equally regardless of which name appears in the study design.

It suggests either lack of peptide chemistry knowledge or deliberate exploitation of naming confusion to create the illusion of product variety. Both names should describe the same amidated heptapeptide — if a supplier differentiates them as distinct offerings, request COAs for both and compare molecular weights and HPLC profiles. Identical values confirm redundant listings; differing values indicate one product may be improperly synthesised or an inactive precursor.

It shouldn’t — they’re the same peptide. Any price difference between ‘Selank’ and ‘Selank Amidate’ from the same supplier reflects pricing strategy, not chemical variance. C-terminal amidation is a standard step in solid-phase peptide synthesis, not a premium modification. Vendors charging more for ‘Amidate’ labelling are exploiting nomenclature confusion.

NH₂ denotes the C-terminal amide group — the structural modification that defines both Selank and Selank Amidate. The full sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ shows the amide (-CONH₂) replacing the terminal carboxyl group (-COOH), which prevents enzymatic degradation by carboxypeptidase B and extends the peptide’s functional half-life.

Selank Amidate and Semax (also C-terminally amidated) are structurally distinct peptides with different mechanisms — Selank modulates BDNF and GABAergic pathways, while Semax acts primarily through melanocortin receptors and BDNF upregulation without direct GABAergic effects. Both require amidation for stability, but the anxiolytic profile of Selank involves GABA modulation absent in Semax, making them complementary rather than interchangeable in research applications.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA